Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER-Stroke: ALD-401 in Ischemic Stroke
NCT01273337Phase 2Unknown
- Sponsor
- Aldagen
- Start
- Mar 2011
- Primary completion
- Jul 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ALD-401 in ischemic stroke, sponsored by Aldagen. Primary endpoint: Safety of Delivery of ALD-401 at 1 year. Status: unknown.
02
Drugs
ALD-401
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT01273337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01273337.